Filament Health Corp. (FLHLF)
| Previous Close | 0.1662 |
| Open | 0.2989 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1783 - 0.2989 |
| 52 Week Range | 0.1662 - 0.3680 |
| Volume | |
| Avg. Volume | 20,589 |
| Market Cap | 29.38M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- CNW Group
FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE LICENSING AGREEMENT
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with Cybin Therapeutics ("CT"), a private therapeutic bioscience company on a mission to discover and develop psilocybin assisted therapeutic protocols to treat mild mood disorders and addictions. Under the agreement, Filament will license PEX010, its botanical psilocybin drug candida
- CNW Group
FILAMENT HEALTH RECOGNIZES THE RESTORATION OF ACCESS TO RESTRICTED DRUGS VIA THE HEALTH CANADA SPECIAL ACCESS PROGRAM
Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), commends the formal restoration of access to restricted drugs through the Health Canada Special Access Program (SAP). The SAP allows health care practitioners to request for patients, on an emergency basis, access to drugs that are not yet approved in Canada. Since 2013, Canadians have been unable to access restricted drugs such as psilocybin and psilocin through the SAP. Thanks to the amendment, this access ha
